← COLLEGIUM PHARMACEUTICAL, INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.7m |
$28.5m
+1564.29%
|
$280.4m
+884.73%
|
$296.7m
+5.81%
|
$310.0m
+4.49%
|
$276.9m
-10.69%
|
$463.9m
+67.56%
|
$566.8m
+22.17%
|
$631.4m
+11.41%
|
$780.6m
+23.62%
|
$808.2m
+3.54%
|
|
| Cost of Revenue | $213k |
$2.6m
+1118.31%
|
$165.7m
+6284.47%
|
$193.7m
+16.89%
|
$130.2m
-32.78%
|
$126.3m
-3.02%
|
$254.4m
+101.54%
|
$240.6m
-5.44%
|
$254.1m
+5.61%
|
$317.3m
+24.87%
|
$323.1m
+1.83%
|
|
| Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization | — | — | — | — | $69.5m |
$59.1m
-15.01%
|
$118.2m
+100.08%
|
$94.8m
-19.76%
|
$88.8m
-6.37%
|
$95.4m
+7.45%
|
$323.1m
+238.64%
|
|
| Gross Profit | $1.5m |
$25.9m
+1627.70%
|
$114.7m
+343.32%
|
$103.0m
-10.19%
|
$179.8m
+74.53%
|
$150.6m
-16.25%
|
$209.5m
+39.09%
|
$326.2m
+55.70%
|
$377.3m
+15.69%
|
$463.3m
+22.77%
|
$485.1m
+4.71%
|
|
| Research and Development Expense | $14.9m | $8.6m | $8.7m | $10.3m | $9.8m | $9.5m | $4.0m | $0 | $0 | — | $0 | |
| Selling, General and Administrative Expense | $80.6m | $92.8m | $126.8m | $116.4m | $113.8m | $119.0m | $172.2m | $159.2m | $210.4m | $284.8m | $327.7m | |
| Marketing and Advertising Expense | $16.3m | $11.0m | $17.5m | — | — | — | — | — | — | $27.8m | — | |
| Amortization of Intangible Assets | $397k | — | $109.8m | $14.8m | $60.7m | $67.2m | — | — | — | $221.9m | — | |
| Operating Expenses | $95.8m | — | — | — | $123.6m | $133.0m | $176.2m | $159.2m | $207.4m | $283.6m | $327.7m | |
| Operating Income (Loss) | ($94.1m) |
($75.4m)
+19.81%
|
($20.7m)
+72.58%
|
($23.7m)
-14.81%
|
$56.2m
+336.79%
|
$17.6m
-68.65%
|
$33.3m
+89.01%
|
$167.0m
+401.10%
|
$169.9m
+1.76%
|
$179.6m
+5.73%
|
$157.4m
-12.38%
|
|
| Investment Income, Net | — | $582k | $1.7m | $1.9m | $232k | $12k | $1.0m | $15.6m | $14.0m | $11.3m | — | |
| Other Nonoperating Income (Expense) | ($94k) | $582k | — | — | — | — | — | — | — | — | — | |
| Interest Expense (non-operating) | $94k | — | $20.1m | $909k | $28.9m | $21.0m | $63.2m | $83.3m | $74.0m | $82.3m | $76.4m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | — | $27.6m | ($3.4m) | ($28.8m) | $75.7m | $98.6m | $92.6m | $77.7m | |
| Income Tax Expense (Benefit) | — | — | — | — | $830k | ($74.9m) | ($3.8m) | $27.6m | $29.4m | $29.7m | $29.8m | |
| Net Income (Loss) Attributable to Parent | ($94.2m) |
($74.9m)
+20.51%
|
($39.1m)
+47.74%
|
($22.7m)
+41.93%
|
$26.8m
+217.74%
|
$71.5m
+167.33%
|
($25.0m)
-134.96%
|
$48.2m
+292.60%
|
$69.2m
+43.68%
|
$62.9m
-9.13%
|
$47.9m
-23.79%
|
|
| Earnings Per Share, Basic | ($3.88) | — | ($1.19) | ($0.68) | $0.78 | $2.05 | ($0.74) | $1.43 | $2.14 | $1.98 | $1.51 | |
| Earnings Per Share, Diluted | ($3.88) | ($2.47) | ($1.19) | ($0.68) | $0.76 | $1.86 | ($0.74) | $1.29 | $1.86 | $1.73 | $1.27 | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | 34.4m | 34.9m | 33.8m | 33.7m | 32.3m | 31.7m | 31.9m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | 35.2m | 41.0m | 33.8m | 41.8m | 40.4m | 39.7m | 36.2m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | — | $103.9m | $301.1m | $320.4m | — | — | — | — | — | — | — |